Combined blockade of PD-1 and CTLA-4 is effective against melanoma and renal cell carcinoma as it can enhance the effector function of CD8+ tumor-infiltrating lymphocytes (TILs) by increasing CD28 costimulation. Here, CTLA4 is linked to melanoma.